Form 4: Warburg Pincus Sells 18M SHC Shares in Secondary Offering

Warburg Pincus entities, a director and 10% owner of Sotera Health Co, sold 18 million shares of common stock for $15.651 per share in a public secondary offering.

Summary

• Warburg Pincus entities, acting as a director and 10% owner of Sotera Health Co (SHC), sold 18,000,000 shares of SHC common stock.
• The sale occurred on November 10, 2025, at a price of $15.651 per share, totaling approximately $281,718,000.
• This transaction was part of an underwritten public secondary offering and was made pursuant to a Rule 10b5-1(c) plan.
• Following the offering, the Warburg Pincus entities beneficially own 43,822,952 shares of SHC common stock.
• The reporting persons include Warburg Pincus & Co. and several related Warburg Pincus investment funds and management entities.

Sentiment

Score: 3

Explanation: A large insider sale by a significant shareholder and director, even if pre-planned, typically carries a negative sentiment as it reduces insider alignment and increases market supply. While it's a common private equity exit strategy, it's not inherently positive for the stock price in the short term.

Positives

• The transaction was executed as an underwritten public secondary offering, suggesting an orderly market process for the sale.
• The sale was conducted under a Rule 10b5-1(c) plan, indicating a pre-planned transaction rather than an immediate reaction to new information.

Negatives

• A significant reduction in beneficial ownership by a major insider (10% owner and director) could be interpreted negatively by the market.
• The sale of 18,000,000 shares represents a substantial divestment of holdings by the Warburg Pincus entities.

Risks

• Increased supply of shares in the market due to the secondary offering could put downward pressure on Sotera Health Co.'s stock price.
• Investor perception of reduced insider confidence following a large sale by a 10% owner and director could negatively impact market sentiment.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Sotera Health Co or the reporting person regarding future operations or financial performance, beyond the execution of a pre-planned sale.

Management Comments

• The Warburg Pincus Entities disclaim beneficial ownership with respect to any shares of Common Stock of the Issuer, except to the extent of its pecuniary interest in such shares of Common Stock, if any.

Industry Context

This filing reflects a significant divestment by a major institutional investor and director, Warburg Pincus, in Sotera Health Co. Such large secondary offerings are common for private equity firms monetizing their investments in public companies, particularly after an IPO or a period of holding. The healthcare sterilization and lab testing industry, in which Sotera Health operates, is generally stable but can be subject to regulatory changes and competitive pressures. This transaction primarily reflects an investment strategy decision by Warburg Pincus rather than a direct commentary on industry trends.

Comparison to Industry Standards

• This Form 4 details an insider transaction, specifically a large secondary offering by a private equity sponsor. Direct comparison to industry-wide operational or financial benchmarks is not applicable here.
• Large secondary offerings by private equity sponsors are a common exit strategy across various industries, including healthcare. The sale price of $15.651 per share would be evaluated by investors against Sotera Health's historical stock performance and peer valuations in the medical device sterilization and lab services sector, such as Steris plc (STE), to gauge the perceived value at the time of sale.

Related Party Transactions

• Warburg Pincus entities, which are directors and 10% owners of Sotera Health Co, sold 18,000,000 shares of common stock in an underwritten public secondary offering. This constitutes a related party transaction as it involves a significant shareholder and director.

Stakeholder Impact

• Shareholders: Potential negative impact due to increased share supply and perception of reduced insider confidence, possibly leading to downward pressure on share price.
• Warburg Pincus Entities: Monetized a significant portion of their investment in Sotera Health Co.

Next Steps

• The filing does not explicitly mention future actions or milestones for Sotera Health Co. The transaction itself is a completed sale by a reporting person.

Key Dates

Recommendation

While a large insider sale by a 10% owner and director can be a negative signal, this transaction was executed under a Rule 10b5-1 plan, indicating it was pre-planned. It represents a private equity firm monetizing a portion of its investment rather than an immediate reaction to adverse company news. Investors should hold and monitor the company's operational performance and future guidance, as this sale primarily reflects an investment strategy decision by Warburg Pincus rather than a fundamental change in Sotera Health's prospects. The remaining significant stake of 43.8 million shares still provides some alignment.

Keywords

Sotera Health, SHC, Warburg Pincus, Insider Sale, Secondary Offering, Form 4, Beneficial Ownership, Equity Sale, Institutional Investor